BioSpace News Archive

Applied Genetic Technologies Corporation announced the pricing of its previously announced underwritten public offering of 7,500,000 shares of its common stock for gross proceeds of approximately $9.8 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by AGTC.

Artelo Biosciences, Inc. announced it has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.

Bimini Health Tech, a commercial-stage medical device company, and Arthrex, Inc., a global leader in minimally invasive orthopedic technology, have entered into an exclusive partnership to globally commercialize Bimini’s Autopose family of products for the harvesting and micro-fragmentation of adipose tissue.

Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a Notice of Allowance has been received from the US Patent and Trademark Office (USPTO) for claims involving a novel method to treat cancer stem cells (CSC’s).

Aerium Therapeutics, a new biopharmaceutical company launching today, is dedicated to discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2 (the virus that causes COVID-19) and its variants, as well as future epidemic and pandemic threats.

Alnylam Pharmaceuticals, Inc. announced today that management will present a company overview at the Stifel 2022 CNS Days, being held virtually, on Monday, March 28, 2022 at 2:00 pm ET

Signifier is the developer of the revolutionary eXciteOSA® medical device for the treatment of sleep disordered breathing, which has now been launched in key markets including the United States of America, Canada, the United Kingdom and Germany.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has advanced VX-147 into pivotal development for people living with proteinuric kidney disease mediated by two mutations in the APOL1 gene (AMKD), which affects approximately 100,000 people in the U.S. and Europe.

Peptilogics will present three papers at the American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting in Chicago March 24.

Spago Nanomedical AB will present a poster summarizing its platform technology for precision imaging and therapy at the scientific conference ACS Spring 2022, which is held digitally on March 20-24.